More recently, ravulizumab (Ultomiris®; Alexion Pharmaceuticals, Inc., Boston), a long-acting C5 inhibitor, has been approved for the treatment of PNH in the USA (December 2018) and several other countries [13, 14]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.